CIMPACT Study Design19

 
 
 
  1. Loading dose of 400 mg Q2W given at Weeks 0, 2, and 4 or Weeks 16, 18, and 20.
  2. Subjects received 400 mg of CIMZIA at Weeks 0, 2, and 4, followed by 200 mg every other week.

ETN, etanercept; LD, loading dose; PASI, Psoriasis Area and Severity Index; Q2W, every 2 weeks.

CIMPACT randomized 559 subjects to receive placebo, CIMZIA 200 mg every other week (following a loading dose of CIMZIA 400 mg at Weeks 0, 2, and 4), CIMZIA 400 mg every other week up to Week 16, or a biologic comparator (up to Week 12). CIMPACT assessed the proportion of patients who achieved a PASI 75 at Week 12 as the primary endpoint. Other evaluated outcomes included PGA of “clear” or “almost clear” on a 5-point scale (0-4) at Week 16, PASI 75 at Week 16, PASI 90 at Week 16, and maintenance of efficacy to Week 48.